Improving the Treatment of Brain Metastases in HER2-Positive Breast Cancers: Eternal Dream or Reality? Results of the NRG Oncology - KROG/RTOG 1119 Phase 2 Randomized Trial and Future Directions

被引:0
|
作者
Kirova, Youlia M. [1 ,2 ]
Loap, Pierre [1 ]
机构
[1] Inst Curie, Dept Radiat Oncol, Paris, France
[2] Univ Versailles St Quentin, Fac Med, Versailles St Quentin, France
关键词
dermal growth factor receptor 2 (HER2) - positive tumors; LAPATINIB PLUS CAPECITABINE;
D O I
10.1016/j.ijrobp.2024.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:1402 / 1403
页数:2
相关论文
共 50 条
  • [21] Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial
    Hurvitz, S. A.
    Kim, S. -B.
    Chung, W. -P.
    Im, S. -A.
    Park, Y. H.
    Hegg, R.
    Kim, M. -H.
    Tseng, L. -M.
    Petry, V.
    Chung, C. -F.
    Iwata, H.
    Hamilton, E.
    Curigliano, G.
    Xu, B.
    Egorov, A.
    Liu, Y.
    Cathcart, J.
    Bako, E.
    Tecson, K.
    Verma, S.
    Cortes, J.
    ESMO OPEN, 2024, 9 (05)
  • [23] A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012
    Fogh, Shannon E.
    Deshmukh, Snehal
    Berk, Lawrence B.
    Dueck, Amylou C.
    Roof, Kevin
    Yacoub, Sherif
    Gergel, Thomas
    Stephans, Kevin
    Rimner, Andreas
    DeNittis, Albert
    Pablo, John
    Rineer, Justin
    Williams, Terence M.
    Bruner, Deborah
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (04): : 786 - 796
  • [24] The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial
    Yamaguchi, Takeshi
    Hozumi, Yasuo
    Sagara, Yasuaki
    Takahashi, Masato
    Yoneyama, Kimiyasu
    Fujisawa, Tomomi
    Osumi, Shozo
    Akabane, Hiromitsu
    Nishimura, Reiki
    Mieno, Makiko Naka
    Mukai, Hirofumi
    SURGICAL ONCOLOGY-OXFORD, 2021, 36 : 51 - 55
  • [25] Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial
    Yan, Min
    Ouyang, Quchang
    Sun, Tao
    Niu, Limin
    Yang, Jin
    Li, Li
    Song, Yuhua
    Hao, Chunfang
    Chen, Zhanhong
    Liu, Zhenzhen
    Lv, Huimin
    Zhang, Mengwei
    Liu, Liping
    Yang, Xiaohong
    Xiao, Huawu
    Gao, Zhichao
    Li, Xiaorui
    Dong, Fangyuan
    Zhang, Lingxiao
    Dong, Danfeng
    Chen, Xiuchun
    Qiao, Jianghua
    Zhang, Guifang
    Zeng, Huiai
    Wang, Jing
    Sun, Huihui
    Feng, Yajing
    Chen, Yuting
    Xia, Fangzhou
    ECLINICALMEDICINE, 2024, 76
  • [26] Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial
    Matikas, Alexios
    Johansson, Hemming
    Gryback, Per
    Bjohle, Judith
    Acs, Balazs
    Boyaci, Ceren
    Lekberg, Tobias
    Fredholm, Hanna
    Elinder, Ellinor
    Margolin, Sara
    Isaksson-Friman, Erika
    Bosch, Ana
    Lindman, Henrik
    Adra, Jamila
    Andersson, Anne
    Agartz, Susanne
    Hellstrom, Mats
    Zerdes, Ioannis
    Hartman, Johan
    Bergh, Jonas
    Hatschek, Thomas
    Foukakis, Theodoros
    CLINICAL CANCER RESEARCH, 2023, 29 (03) : 532 - 540
  • [27] Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells - results from the randomized phase III DETECT III trial
    Fehm, Tanja
    Mueller, Volkmar
    Banys-Paluchowski, Maggie
    Fasching, Peter A.
    Friedl, Thomas W. P.
    Hartkopf, Andreas
    Huober, Jens
    Loehberg, Christian
    Rack, Brigitte
    Riethdorf, Sabine
    Schneeweiss, Andreas
    Wallwiener, Diethelm
    Meier-Stiegen, Franziska
    Hoffmann, Oliver
    Muller, Lothar
    Wimberger, Pauline
    Ruckhaeberle, Eugen
    Blohmer, Jens
    Janni, Wolfgang
    CANCER RESEARCH, 2021, 81 (04)
  • [28] COMBINATION OF TRASTUZUMAB, OXALIPLATIN AND DOCETAXEL AS FIRST LINE TREATMENT IN HER2-POSITIVE ADVANCED BREAST CANCER PATIENTS: PRELIMINARY RESULTS OF A PHASE II TRIAL (HOT TRIAL)
    Amoroso, Domenico
    Donati, Sara
    Rondini, Marianna
    Valsuani, Chiara
    Siclari, Olimpia
    Puccetti, Cheti
    Tartarelli, Gianna
    Puccinelli, Paolo
    Giannessi, Piergiorgio
    Falcone, Alfredo
    Camerini, Andrea
    ANNALS OF ONCOLOGY, 2009, 20
  • [29] Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial
    Liu, Yunjiang
    Zhang, Shuo
    CANCER RESEARCH, 2020, 80 (04)
  • [30] Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
    Bartsch, Rupert
    Berghoff, Anna Sophie
    Furtner, Julia
    Marhold, Maximilian
    Bergen, Elisabeth Sophie
    Roider-Schur, Sophie
    Mair, Maximilian Johannes
    Starzer, Angelika Martina
    Forstner, Heidrun
    Rottenmanner, Beate
    Aretin, Marie-Bernadette
    Dieckmann, Karin
    Bago-Horvath, Zsuzsanna
    Haslacher, Helmuth
    Widhalm, Georg
    Ilhan-Mutlu, Ayseguel
    Minichsdorfer, Christoph
    Fuereder, Thorsten
    Szekeres, Thomas
    Oehler, Leopold
    Gruenberger, Birgit
    Pfeiler, Georg
    Singer, Christian
    Weltermann, Ansgar
    Berchtold, Luzia
    Preusser, Matthias
    NEURO-ONCOLOGY, 2024, 26 (12) : 2305 - 2315